Market Exclusivity "Give-Away" Gone In Bioterror Bill

Law360, New York (October 24, 2005, 12:00 AM EDT) -- The contentious “wildcard” provision for market exclusivity has been removed prior to a vote from an updated Biodefense bill on Capitol Hill, easing concerns of the generic drug industry while leaving intact other controversial language.

The so-called “BioShield II” bill has been approved by the Senate Committee on Health, Education, Labor and Pension (HELP). It was penned and introduced by Senator Richard Burr (R-NC) to prompt cooperation between the private and public sectors in drug development. Burr is chairman of the HELP Subcommittee on Bioterrorism and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.